EXPERIMENTAL HEMATOLOGY

Scope & Guideline

Transforming Hematology with Groundbreaking Research

Introduction

Delve into the academic richness of EXPERIMENTAL HEMATOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0301-472x
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1973 to 2024
AbbreviationEXP HEMATOL / Exp. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

EXPERIMENTAL HEMATOLOGY focuses on advancing the understanding of hematopoiesis, hematological malignancies, and related therapeutic interventions. The journal emphasizes innovative research methodologies and interdisciplinary approaches to address key challenges in the field.
  1. Hematopoiesis and Stem Cell Biology:
    The journal covers extensive research on the mechanisms of hematopoiesis, including the development, differentiation, and function of hematopoietic stem cells (HSCs), progenitor cells, and their niches.
  2. Hematological Malignancies:
    Research on the molecular and cellular basis of hematological cancers, including leukemias, lymphomas, and myeloproliferative neoplasms, is a core area of focus, particularly mechanisms of tumorigenesis and therapeutic resistance.
  3. Therapeutic Innovations:
    EXPERIMENTAL HEMATOLOGY publishes studies on novel therapeutic strategies, including gene therapy, immunotherapy, and targeted treatments for hematological diseases, highlighting translational research.
  4. Microenvironment and Niche Interactions:
    The journal emphasizes the role of the bone marrow microenvironment and other niches in regulating hematopoietic cell behavior, interactions between different cell types, and their impact on disease.
  5. Epigenetics and Transcriptional Regulation:
    Research exploring the epigenetic landscape and transcriptional control mechanisms governing hematopoietic development and malignancies is prominently featured, reflecting the journal's commitment to understanding gene regulation.
  6. Systemic and Local Regulation of Hematopoiesis:
    Studies addressing the systemic factors influencing hematopoiesis and the local signals from the microenvironment that modulate hematopoietic function are integral to the journal's scope.
EXPERIMENTAL HEMATOLOGY is currently witnessing several emerging themes that reflect the cutting-edge advancements in hematology research. These trends indicate a shift towards more innovative methodologies and interdisciplinary approaches.
  1. Single-Cell Technologies:
    An increasing number of studies are employing single-cell RNA sequencing and other single-cell technologies to elucidate the heterogeneity of hematopoietic stem and progenitor cells, providing insights into their function and regulation.
  2. Metabolic Regulation:
    Research focusing on the metabolic pathways that influence hematopoietic stem cell function and differentiation is gaining prominence, highlighting the interplay between metabolism and cell fate.
  3. Inflammation and Immune Interactions:
    The role of inflammation and immune responses in regulating hematopoiesis and hematological malignancies is an emerging theme, with studies investigating how these factors influence disease progression.
  4. Gene Editing and Genetic Models:
    There is a notable increase in studies utilizing advanced gene editing techniques (e.g., CRISPR/Cas9) to model hematological diseases and explore genetic factors contributing to malignancies.
  5. Epitranscriptomics:
    The exploration of RNA modifications (e.g., m6A methylation) and their impact on gene expression and hematopoietic function is an emerging area of interest, reflecting the evolving understanding of post-transcriptional regulation.
  6. Therapeutic Targeting of the Microenvironment:
    Research targeting the bone marrow microenvironment to enhance hematopoietic stem cell recovery and improve treatment outcomes in hematological malignancies is gaining traction, indicating a shift towards niche-focused therapies.

Declining or Waning

While EXPERIMENTAL HEMATOLOGY continues to thrive in many areas, certain themes appear to be waning or experiencing decreased publication frequency. This could reflect shifts in research focus or advances in understanding that render some topics less prominent.
  1. Traditional Animal Models:
    Research utilizing conventional animal models for hematopoiesis and leukemia studies is less frequently published, potentially due to the increasing adoption of advanced in vitro and humanized models.
  2. Basic Hematology without Translational Focus:
    Papers focusing solely on basic hematological research without clear translational implications are becoming less common, as the field increasingly emphasizes studies that bridge basic science with clinical application.
  3. Single-Agent Therapeutic Studies:
    The publication of studies focusing exclusively on single-agent therapies without exploring combination strategies or innovative approaches appears to be declining, reflecting a shift towards more complex treatment paradigms.
  4. Epidemiological Studies:
    There has been a noticeable decrease in the publication of epidemiological studies related to hematological disorders, possibly due to a growing emphasis on mechanistic and experimental research.

Similar Journals

Therapeutic Advances in Hematology

Elevating therapeutic practices in hematology.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Unraveling Complexities in Molecular Biology
Publisher: BEGELL HOUSE INCISSN: 1045-4403Frequency: 3 issues/year

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, published by BEGELL HOUSE INC, serves as a vital resource within the fields of Genetics and Molecular Biology. With the ISSN 1045-4403 and E-ISSN 2162-6502, this journal has been contributing to scientific discourse since 1990 and is projected to continue its publication until 2024. Despite its classification in the Q3 quartile for both Genetics and Molecular Biology, its impact on the research community is significant, as evidenced by its diverse range of critical reviews that synthesize and analyze emerging trends and foundational studies in gene expression. The journal, located in the United States at 50 North St, Danbury, CT 06810, offers a platform for researchers, professionals, and students to engage with innovative ideas and methodologies that drive forward the understanding of gene regulatory mechanisms in eukaryotes. Although it currently does not offer open access, the journal's content remains crucial for those dedicated to advancing knowledge in the intricacies of genetic expression.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Illuminating Cellular Processes Through Open Access Research
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

CELL PROLIFERATION

Pioneering Research for a Healthier Tomorrow
Publisher: WILEYISSN: 0960-7722Frequency: 12 issues/year

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

Advances in Cancer Biology-Metastasis

Advancing Understanding, Transforming Outcomes.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

CURRENT OPINION IN HEMATOLOGY

Transforming contemporary issues into clinical solutions.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Pioneering research in cell and molecular dynamics.
Publisher: ELSEVIERISSN: 0167-4889Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH is a premier journal published by Elsevier, dedicated to advancing the fields of cell biology and molecular biology. Established in 1982, this influential journal has been at the forefront of scientific research and innovation, currently holding esteemed positions with a Q2 ranking in Cell Biology and a Q1 ranking in Molecular Biology for 2023, reflecting its commitment to high-quality scholarship. With an impressive impact factor, it ranks in the 82nd and 78th percentiles for Molecular Biology and Cell Biology, respectively, amongst its peers. Researchers, professionals, and students will find this journal to be an invaluable resource for exploring the latest discoveries and methodologies in the molecular mechanisms underlying cellular functions. Although it is not an open-access journal, the insights offered in its pages contribute significantly to the scientific community's understanding of cellular and molecular processes, ensuring it remains a vital platform for disseminating cutting-edge research.

Cell Discovery

Unveiling Breakthroughs in Life Sciences
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Cell Discovery, published by SPRINGERNATURE, is a premier open access journal in the dynamic fields of Biochemistry, Cell Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has established itself as a key platform for disseminating high-impact research and is recognized with a Q1 ranking across all its core categories for the year 2023. With its remarkable Scopus rankings—7th in Genetics, 9th in Biochemistry, 13th in Molecular Biology, and 15th in Cell Biology—Cell Discovery positions itself among the elite journals in life sciences, showcasing the most innovative breakthroughs and comprehensive reviews. Based in the United Kingdom, this journal operates under an open access model, ensuring that groundbreaking discoveries are readily available to researchers, professionals, and students around the globe. With a commitment to advancing scientific knowledge, Cell Discovery welcomes contributions that push the frontiers of our understanding in cellular and genetic sciences.

Journal of Hematology & Oncology

Fostering Excellence in Hematology and Oncology Scholarship
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

BIOCELL

Connecting Researchers for a Deeper Understanding of Life Sciences
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.